ContractTechnology Transfer, Technical Cooperation and License Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
ContractExclusive International Distributor Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
TECHNOLOGY EVALUATION AGREEMENTTechnology Evaluation Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories • New York
This AGREEMENT, effective this 13th day of September, 2019 (hereinafter referred to as the “Effective Date”), is made by and between [***], a [***] (hereinafter referred to as “[***]”), and Ares Genetics GmbH, a company registered in Vienna, Austria, whose registered office is at Karl-Farkas-Gasse 18, 1030 Vienna, Austria (hereinafter referred to as (“COMPANY”). Each of [***] and COMPANY may be referred to herein individually as a “Party” and collectively as the “Parties.”
WORK ORDER AGREEMENTWork Order Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
This work order (“Work Order”) shall be effective as of the Effective Date below. It is subject to the terms of the Services Frame Agreement (“Agreement”) between Sandoz and Service Provider/Institution dated 14 December zoi8.
Amendment 1Exclusive International Distribution Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
This Is Amendment 1 to the Exclusive International Distribution Agreement (“Agreement”) between Curetis GmbH (“Curetis”) and Beijing Clear Biotech (“BCB”) (collectively the Parties), which was signed September 25, 2015.
Assumption of contract by and betweenAssumption of Contract • December 20th, 2019 • Opgen Inc • Services-medical laboratories
ContractFirst Amendment Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
ContractServices Frame Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
ContractLicense Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
Non-Exclusive Patent License and Research Collaboration AgreementNon-Exclusive Patent License and Research Collaboration Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
This is a patent license and research collaboration agreement (the “Agreement”) dated October 5, 2015 (the “Effective Date”) between Acumen Research Laboratories Pte Ltd, a company under Singapore law with a registered seat at Diagnostics Development (DxD) Hub,10 Biopolis Road, #03-01, Singapore 138670 (hereinafter referred to as “Licensor”), and Curetis AG, a company under German law with a registered seat at Max-Eyth-Strasse 42, 71088 Holzgerlingen, Germany (hereinafter referred to as “Licensee”). Each of Licensee and Licensor may be referred to herein as a “Party” or collectively as the “Parties”.
ContractAmendment and Restatement Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories • England and Wales
Certain identified information has been excluded from this Exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
ContractAuthorization and Supply Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
ContractExclusive International Distribution Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
Memorandum of Understanding (MoU) Between Curetis GmbH, Ares Genetics GmbH and MGI Tech Co., Ltd.Memorandum of Understanding (Mou) • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Progress in the prevention and treatment of infectious diseases has vastly improved the survival chances and quality of life of patients across the globe. In recent years however, spreading of antimicrobial resistance through indiscriminate use of antibiotics has become one of the most severe threats to modern medicine. Better and faster ways to diagnose microbial infections are key to a more targeted use of antibiotics to slow down the development of resistance to current and future drugs.
First Amendment to License AgreementLicense Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
This first Amendment (hereinafter “First Amendment”) is dated September 18, 2019 (the “First Amendment Effective Date”) and amends the License Agreement, dated February 18th, 2019 (the “Agreement”) by and between ARES Genetics GmbH, Karl-Farkas-Gasse 18, 1030 Vienna, Austria (“ARES”) and QIAGEN GmbH, Qiagen Str. 1, 40724 Hilden, Germany (“QIAGEN”), which was not amended previously. Both parties in the following also each or collectively referred to as “Party” or “Parties”.
ContractTechnology Purchase Agreement • December 20th, 2019 • Opgen Inc • Services-medical laboratories
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. [***] indicates that information has been redacted.
